| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MDS009 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DTWD1抗体的虚构参考文献示例(仅供格式参考，非真实文献)：
---
1. **标题**: *Development and Characterization of a Polyclonal Antibody Against Human DTWD1 Protein*
**作者**: Zhang L. et al. (2021)
**摘要**: 本研究报道了一种新型兔源多克隆抗体的开发，通过重组人DTWD1蛋白免疫制备。抗体经ELISA和Western blot验证具有高特异性，可用于检测内源性DTWD1在细胞质中的定位，并成功应用于免疫荧光染色和蛋白质相互作用研究。
2. **标题**: *DTWD1 Overexpression in Hepatocellular Carcinoma: A Prognostic Biomarker Identified by Immunohistochemistry*
**作者**: Tanaka K. et al. (2019)
**摘要**: 利用DTWD1特异性抗体对肝癌组织进行免疫组化分析，发现DTWD1在肿瘤组织中显著高表达，且与患者生存率负相关。研究提示DTWD1可能作为肝癌诊断的潜在标志物，抗体验证了其临床样本中的表达模式。
3. **标题**: *DTWD1 Regulates Wnt/β-Catenin Signaling via Protein Interaction Mapping*
**作者**: Müller F. et al. (2020)
**摘要**: 通过Co-IP和抗体介导的蛋白复合体捕获，揭示了DTWD1与β-catenin的直接结合，调控Wnt信号通路活性。研究结合CRISPR敲除模型，证实抗体在功能研究中的可靠性。
4. **标题**: *Epitope Mapping of DTWD1 Antibodies for Structural Analysis*
**作者**: Chen R. et al. (2022)
**摘要**: 采用肽段扫描和质谱技术，确定了商业化DTWD1抗体的线性表位位于C端结构域(氨基酸残基150-200)，为后续结构解析及功能缺失实验提供了关键工具。
---
**注意**：以上文献为模拟示例，实际研究中请通过PubMed、Google Scholar等平台检索真实文献(关键词：DTWD1 antibody, DTWD1 protein, immunohistochemistry)。
The DTWD1 (Distant Tryptophan Domain-containing Protein 1) antibody is a tool used to study the DTWD1 protein, a conserved eukaryotic protein implicated in RNA modification and translation regulation. DTWD1 contains a tryptophan-aspartate (WD) repeat domain, a structural motif often involved in protein-protein interactions. Research suggests DTWD1 interacts with the Elongator complex, a multi-subunit enzyme critical for tRNA wobble uridine modifications (e.g., 5-methoxycarbonylmethyluridine, mcm⁵U). These modifications ensure translational fidelity and efficiency by stabilizing tRNA structure and codon-anticodon pairing. Dysregulation of DTWD1 or Elongator activity is linked to neurodevelopmental disorders, cancer, and metabolic diseases.
DTWD1 antibodies (polyclonal or monoclonal) are typically generated against recombinant protein fragments or synthetic peptides. They enable detection of endogenous DTWD1 via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Validation often includes knockout cell line controls to confirm specificity. Current research focuses on DTWD1's role in cellular stress responses, its interaction networks, and its potential as a biomarker or therapeutic target in diseases associated with translational dysfunction. Commercial availability varies, with common hosts including rabbit and mouse.
×
